

SYNAPTICS Inc  
Form 10-Q  
February 03, 2016  
c

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 26, 2015

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission file number 000-49602

SYNAPTICS INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware 77-0118518  
(State or other jurisdiction of (I.R.S. Employer

incorporation or organization) Identification No.)

1251 McKay Drive

San Jose, California 95131

(Address of principal executive offices) (Zip code)

(408) 904-1100

Edgar Filing: SYNAPTICS Inc - Form 10-Q

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.:

Large accelerated filer

Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Number of shares of Common Stock outstanding at January 29, 2016: 36,667,202

SYNAPTICS INCORPORATED

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED DECEMBER 26, 2015

TABLE OF CONTENTS

|  | Page |
|--|------|
| <u>Part I. Financial Information</u>   |      |
| Item 1. <u>Condensed Consolidated Financial Statements (Unaudited):</u>  | 3    |
| <u>Condensed Consolidated Balance Sheets—December 31, 2015 and June 30, 2015</u>                                       | 3    |
| <u>Condensed Consolidated Statements of Income—Three and Six Months Ended December 31, 2015 and 2014</u>               | 4    |
| <u>Condensed Consolidated Statements of Comprehensive Income—Three and Six Months Ended December 31, 2015 and 2014</u> | 5    |
| <u>Condensed Consolidated Statements of Cash Flows—Six Months Ended December 31, 2015 and 2014</u>                     | 6    |
| <u>Notes to Condensed Consolidated Financial Statements</u>  | 7    |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>                   | 18   |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 27   |
| Item 4. <u>Controls and Procedures</u>   | 27   |
| <u>Part II. Other Information</u>  |      |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 28   |
| Item 6. <u>Exhibits</u>  | 29   |
| <u>Signatures</u>  | 30   |

## PART I—FINANCIAL INFORMATION

## ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except par value and share amounts)

(unaudited)

|  | December<br>31,<br>2015 | June 30,<br>2015 |
|--|-------------------------|------------------|
| <b>ASSETS</b>  |                         |                  |
| Current Assets:  |                         |                  |
| Cash and cash equivalents  | \$ 372.0                | \$ 399.9         |
| Accounts receivable, net of allowances of \$2.3 and \$2.9 at December 31, 2015 and June 30, 2015, respectively | 337.0                   | 324.6            |
| Inventories  | 136.6                   | 140.2            |
| Prepaid expenses and other current assets  | 46.7                    | 51.3             |
| Total current assets   | 892.3                   | 916.0            |
| Property and equipment at cost, net of accumulated depreciation of \$76.9                                      |                         |                  |
| and \$67.4 at December 31, 2015 and June 30, 2015, respectively  | 116.0                   | 123.4            |
| Goodwill   | 206.8                   | 206.8            |
| Acquired intangibles, net  | 201.9                   | 235.4            |
| Non-current other assets   | 36.3                    | 37.8             |
|  | \$ 1,453.3              | \$ 1,519.4       |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                         |                  |
| Current Liabilities:   |                         |                  |
| Accounts payable   | \$ 166.6                | \$ 188.5         |
| Accrued compensation   | 43.5                    | 35.9             |
| Income taxes payable   | 27.5                    | 34.7             |
| Acquisition-related liabilities  | 68.4                    | 102.2            |
| Other accrued liabilities  | 77.1                    | 74.1             |
| Current portion of long-term debt  | 15.0                    | 11.3             |
| Total current liabilities  | 398.1                   | 446.7            |
| Long-term debt, net of issuance costs  | 223.7                   | 231.1            |
| Deferred tax liabilities   | 25.8                    | 33.9             |
| Other long-term liabilities  | 41.9                    | 14.6             |
| Total liabilities  | 689.5                   | 726.3            |

## Stockholders' Equity:

## Common stock:

\$0.001 par value; 120,000,000 shares authorized,

59,038,874 and 58,249,107 shares issued, and 36,650,662 and 37,529,608

|  |            |            |
|--|------------|------------|
| shares outstanding, at December 31, 2015 and June 30, 2015, respectively | 0.1        | 0.1        |
| Additional paid-in capital   | 882.6      | 843.8      |
| Treasury stock: 22,388,212 and 20,719,499 common treasury shares at      |            |            |
| December 31, 2015 and June 30, 2015, respectively, at cost               | (776.7 )   | (651.7 )   |
| Accumulated other comprehensive income                                   | 5.9        | 7.8        |
| Retained earnings  | 651.9      | 593.1      |
| Total stockholders' equity   | 763.8      | 793.1      |
|  | \$ 1,453.3 | \$ 1,519.4 |

See accompanying notes to condensed consolidated financial statements (unaudited).

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in millions, except per share data)

(unaudited)

|  | Three Months<br>Ended<br>December 31, |         | Six Months<br>Ended<br>December 31, |         |
|--|---------------------------------------|---------|-------------------------------------|---------|
|  | 2015                                  | 2014    | 2015                                | 2014    |
| Net revenue                                    | \$470.5                               | \$463.7 | \$940.5                             | \$746.5 |
| Cost of revenue                                | 305.3                                 | 336.9   | 611.5                               | 499.4   |
| Gross margin                                   | 165.2                                 | 126.8   | 329.0                               | 247.1   |
| Operating expenses:                            |                                       |         |                                     |         |
| Research and development                       | 78.6                                  | 77.3    | 159.1                               | 134.8   |
| Selling, general, and administrative           | 41.0                                  | 22.0    | 81.2                                | 52.7    |
| Acquired intangibles amortization              | 4.6                                   | 4.6     | 9.3                                 | 4.9     |
| Change in contingent consideration             | (4.3 )                                | (7.1 )  | (1.6 )                              | (11.6 ) |
| Restructuring costs                            | -                                     | -       | 1.9                                 | -       |
| Total operating expenses                       | 119.9                                 | 96.8    | 249.9                               | 180.8   |
| Operating income                               | 45.3                                  | 30.0    | 79.1                                | 66.3    |
| Interest and other expense, net                | (0.8 )                                | (0.7 )  | (1.6 )                              | (0.1 )  |
| Income before provision for income taxes       | 44.5                                  | 29.3    | 77.5                                | 66.2    |
| Provision for income taxes                     | 9.5                                   | 8.3     | 18.7                                | 18.6    |
| Net income                                     | \$35.0                                | \$21.0  | \$58.8                              | \$47.6  |
| Net income per share:                          |                                       |         |                                     |         |
| Basic  | \$0.96                                | \$0.57  | \$1.61                              | \$1.29  |
| Diluted  | \$0.93                                | \$0.55  | \$1.55                              | \$1.22  |
| Shares used in computing net income per share: |                                       |         |                                     |         |
| Basic  | 36.4                                  | 36.5    | 36.6                                | 36.9    |
| Diluted  | 37.7                                  | 38.2    | 38.0                                | 38.9    |

See accompanying notes to condensed consolidated financial statements (unaudited).

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in millions)

(unaudited)

|  | Three<br>Months<br>Ended<br>December 31, |        | Six Months<br>Ended<br>December 31, |        |
|--|--|--------|-------------------------------------|--------|
|  | 2015                                     | 2014   | 2015                                | 2014   |
| Net income   | \$35.0                                   | \$21.0 | \$58.8                              | \$47.6 |
| Other comprehensive income:  |  |        |                                     |        |
| Change in unrealized net loss on investments   | (0.7)                                    | 0.1    | (1.0)                               | 0.2    |
| Reclassification from accumulated other comprehensive<br>income to interest income for accretion of<br>non-current investments | (0.5)                                    | (0.3)  | (0.9)                               | (0.7)  |
| Net current-period other comprehensive income  | (1.2)                                    | (0.2)  | (1.9)                               | (0.5)  |
| Comprehensive income   | \$33.8                                   | \$20.8 | \$56.9                              | \$47.1 |

See accompanying notes to condensed consolidated financial statements (unaudited).

## SYNAPTICS INCORPORATED AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)

|   | Six Months<br>Ended<br>December 31, |         |
|---|-------------------------------------|---------|
|   | 2015                                | 2014    |
| Cash flows from operating activities  |                                     |         |
| Net income  | \$58.8                              | \$47.6  |
| Adjustments to reconcile net income to net cash provided by operating activities: |                                     |         |
| Share-based compensation costs  | 25.9                                | 20.2    |
| Depreciation and amortization   | 15.5                                | 10.5    |
| Acquired intangibles amortization   | 37.9                                | 47.9    |
| Accretion and remeasurement of contingent consideration liability                 | (1.6 )                              | (11.6 ) |
| Deferred taxes  | (8.4 )                              | (2.6 )  |
| Impairment recovery on investments  | -                                   | (0.2 )  |
| Impairment of property and equipment  | 2.4                                 | -       |
| Non-cash interest   | (0.9 )                              | (0.7 )  |
| Amortization of debt issuance costs   | 0.4                                 | 0.3     |
| Foreign currency remeasurement (gain)/loss  | 0.7                                 | (7.2 )  |
| Changes in operating assets and liabilities, net of acquisitions:                 |                                     |         |
| Accounts receivable, net  | (12.4 )                             | (10.1 ) |
| Inventories   | 3.6                                 | (56.6 ) |
| Prepaid expenses and other current assets   | 2.7                                 | 22.0    |
| Other assets  | 2.4                                 | 4.8     |
| Accounts payable  | (17.7 )                             | (3.4 )  |
| Accrued compensation  | 7.5                                 | (0.6 )  |
| Acquisition-related liabilities   | (9.6 )                              | -       |
| Income taxes payable  | (4.6 )                              | (29.3 ) |
| Other accrued liabilities   | 4.2                                 | 13.4    |
| Net cash provided by operating activities   | 106.8                               | 44.4    |
| Cash flows from investing activities  |                                     |         |
| Proceeds from sales of short-term investments                                     | 0.6                                 | -       |
| Proceeds from sales of non-current investments                                    | -                                   | 4.9     |
| Acquisition of business, net of cash acquired                                     | -                                   | (293.8) |
| Purchase of intangible assets   | (4.4 )                              | -       |
| Purchases of property and equipment   | (15.1 )                             | (34.3 ) |
| Net cash used in investing activities   | (18.9 )                             | (323.2) |
| Cash flows from financing activities  |                                     |         |
| Payment of acquisition-related liabilities  | -                                   | (7.7 )  |
| Payment of debt   | (3.8 )                              | -       |
| Purchases of treasury stock   | (125.0)                             | (90.6 ) |



Edgar Filing: SYNAPTICS Inc - Form 10-Q

|  |         |         |
|--|---------|---------|
| Proceeds from issuance of shares                             | 19.5    | 16.8    |
| Proceeds from issuance of long-term debt                     | -       | 245.4   |
| Payment of debt issuance costs                               | (0.3 )  | (0.4 )  |
| Excess tax benefit from share-based compensation             | 4.7     | 7.4     |
| Payroll taxes for deferred stock and market stock units      | (11.2 ) | (8.2 )  |
| Net cash provided from/(used in) financing activities        | (116.1) | 162.7   |
| Effect of exchange rate changes on cash and cash equivalents | 0.3     | (3.6 )  |
| Net decrease in cash and cash equivalents                    | (27.9 ) | (119.7) |
| Cash and cash equivalents at beginning of period             | 399.9   | 447.2   |
| Cash and cash equivalents at end of period                   | \$372.0 | \$327.5 |
| <b>Supplemental disclosures of cash flow information</b>     |         |         |
| Cash paid for taxes  | \$25.8  | \$40.6  |
| Cash refund on taxes   | \$10.8  | \$-     |
| Non-cash investing and financing activities:                 |         |         |
| Property and equipment received but unpaid                   | \$3.5   | \$2.1   |
| Common stock issued pursuant to acquisition                  | \$-     | \$21.5  |

See accompanying notes to condensed consolidated financial statements (unaudited).

SYNAPTICS INCORPORATED AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, and U.S. generally accepted accounting principles, or U.S. GAAP. However, certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to SEC rules and regulations. In our opinion, the financial statements include all adjustments, which are of a normal and recurring nature and necessary for the fair presentation of the results of the interim periods presented. The results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future period. These financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended June 27, 2015.

The consolidated financial statements include our financial statements and those of our wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.

Our fiscal year is the 52- or 53-week period ending on the last Saturday in June. Our fiscal 2016 and 2015 years are 52-week periods ending on June 25, 2016 and June 27, 2015, respectively. The quarterly fiscal periods presented in this report were 13-week periods and 26-week periods for the three and six months ended December 26, 2015 and December 27, 2014, respectively. For ease of presentation, the accompanying consolidated financial statements have been shown as ending on calendar quarter end dates as of and for all periods presented, unless otherwise indicated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to revenue recognition, allowance for doubtful accounts, cost of revenue, inventories, loss on purchase commitments, product warranty, accrued liabilities, share-based compensation costs, provision for income taxes, deferred income tax asset valuation allowances, uncertain tax positions, goodwill, intangible assets, investments, contingent consideration liability and loss contingencies. We base our estimates on historical experience, applicable laws and regulations, and various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Foreign Currency Transactions and Foreign Exchange Contracts

The U.S. dollar is our functional and reporting currency. We remeasure our monetary assets and liabilities not denominated in the functional currency into U.S. dollar equivalents at the rate of exchange in effect on the balance sheet date. We measure and record non-monetary balance sheet accounts at the historical rate in effect at the date of

transaction. We remeasure foreign currency expenses at the weighted average exchange rate in the month that the transaction occurred. These foreign currency transactions and remeasurement gains and losses, resulted in a net gain of \$0.1 million and a net loss of \$3.0 million in the three and six months ended December 31, 2015, and resulted in a net gain of \$15.1 million and \$14.9 million in the three and six months ended December 31, 2014. They are included in selling, general, and administrative expenses in the condensed consolidated statements of income.

We enter into foreign currency contracts to manage exposure related to certain foreign currency obligations. The foreign currency contracts are not designated as hedging instruments and, accordingly, are not subject to hedge accounting. In fiscal year 2015, we entered into foreign currency forward contracts to purchase Japanese yen, using U.S. dollars. As of December 31, 2015, we had outstanding foreign currency forward contracts totaling ¥7.3 billion for a total of \$60.5 million, at an average exchange rate of 120.51. The value date of the foreign currency forward contracts is March 11, 2016. The net fair value of the outstanding foreign currency forward contracts is disclosed in Note 4 Fair Value, and is recorded as a liability under other accrued liabilities in the condensed consolidated balance sheets. In the three and six months ended December 31, 2015, we recognized net unrealized losses of \$0.4 million and net unrealized gains of \$1.2 million, respectively, on the foreign currency forward contracts, which are recorded in selling, general, and administrative expenses in the condensed consolidated statements of income.

## 2. Revenue Recognition

We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred and title has transferred, the price is fixed or determinable, and collection is reasonably assured. We accrue for estimated sales returns, incentives, and other allowances at the time we recognize revenue. Our products contain embedded firmware and software, which together with, or consisting of, our ASIC chip, deliver the essential functionality of our products and, as such, software revenue recognition guidance is not applicable. Our sales to distributors are made under agreements that do not provide for price adjustments after purchase and provide for only limited return rights under product warranty. Revenue on these sales is recognized in the same manner as sales to our non-distributor customers.

## 3. Net Income Per Share

The computation of basic and diluted net income per share was as follows (in millions, except per share data):

|                                       | Three<br>Months<br>Ended<br>December<br>31,<br>2015 |        | Six Months<br>Ended<br>December<br>31,<br>2014 |        |
|---------------------------------------|---|--------|--|--------|
| <b>Numerator:</b>                     |   |        |  |        |
| Net income                            | \$35.0  | \$21.0 | \$58.8   | \$47.6 |
| <b>Denominator:</b>                   |   |        |  |        |
| Shares, basic                         | 36.4  | 36.5   | 36.6   | 36.9   |
| Effect of dilutive share-based awards | 1.3   | 1.7    | 1.4  | 2.0    |
| Shares, diluted                       | 37.7  | 38.2   | 38.0   | 38.9   |
| <b>Net income per share:</b>          |   |        |  |        |
| Basic                                 | \$0.96  | \$0.57 | \$1.61   | \$1.29 |
| Diluted                               | \$0.93  | \$0.55 | \$1.55   | \$1.22 |

Our basic net income per share amounts for each period presented have been computed using the weighted average number of shares of common stock outstanding. Our diluted net income per share amounts for each period presented include the weighted average effect of potentially dilutive shares. We use the “treasury stock” method to determine the dilutive effect of our stock options, deferred stock units, or DSUs, and market stock units, or MSUs.

Dilutive net income per share amounts do not include the potential weighted average effect of 969,730 and 532,982 shares of common stock related to certain share-based awards that were outstanding during the three months ended December 31, 2015 and 2014, respectively, and 717,991 and 332,892 shares of common stock related to certain share-based awards that were outstanding during the six months ended December 31, 2015 and 2014, respectively. These share-based awards were not included in the computation of diluted net income per share because their effect would have been antidilutive.

## 4. Fair Value

Financial assets and liabilities, measured at fair value on a recurring basis by level within the fair value hierarchy, consisted of the following (in millions):

|   | December 31,<br>2015 |            |            | June 30,<br>2015 |            |            |
|---|----------------------|------------|------------|------------------|------------|------------|
|   | Level<br>1           | Level<br>2 | Level<br>3 | Level<br>1       | Level<br>2 | Level<br>3 |
| <b>Assets:</b>  |                      |            |            |                  |            |            |
| Money market funds  | \$345.2              | \$—        | \$—        | \$376.3          | \$—        | \$—        |
| Auction rate securities   | —                    | —          | 14.2       | —                | —          | 15.8       |
| Total available-for-sale securities                                     | \$345.2              | \$—        | \$14.2     | \$376.3          | \$—        | \$15.8     |
| <b>Liabilities:</b>   |                      |            |            |                  |            |            |
| Contingent consideration liabilities recorded for business combinations | \$—                  | \$—        | \$33.0     | \$—              | \$—        | \$44.2     |
| Foreign currency contract liabilities                                   | \$—                  | \$0.1      | \$—        | \$—              | \$1.3      | \$—        |

In our condensed consolidated balance sheets as of December 31, 2015 and June 30, 2015, money market balances were included in cash and cash equivalents, and auction rate securities, or ARS investments, were included in non-current other assets except for \$600,000 of the ARS investments were included in prepaid expenses and other current assets as of June 30, 2015.

The contingent consideration liability recorded for business combinations was included in acquisition-related liabilities as of December 31, 2015 and June 30, 2015, respectively.

We measure our foreign currency contracts at fair value on a recurring basis. We utilized Level 2 inputs to value the foreign currency forward contracts. Specifically, we utilized quoted prices for similar assets and liabilities in markets that are not active. Key inputs for the foreign currency forward contracts are spot rates and yield curves for the respective currencies. The foreign currency contracts were included in other accrued liabilities as of December 31, 2015 and June 30, 2015.

Changes in fair value of our Level 3 financial assets as of December 31, 2015 were as follows (in millions):

|                                 |         |
|---------------------------------|---------|
| Balance as of June 30, 2015     | \$ 15.8 |
| Net loss                        | (1.0 )  |
| Redemptions                     | (0.6 )  |
| Balance as of December 31, 2015 | \$ 14.2 |

Changes in fair value of our Level 3 contingent consideration liabilities as of December 31, 2015 were as follows (in millions):

|   |        |
|---|--------|
| Balance as of June 30, 2015                           | \$44.2 |
| Cash settlement of contingent consideration liability | (9.6 ) |
| Accretion and rereasurement                           | (1.6 ) |
| Balance as of December 31, 2015                       | \$33.0 |

In connection with our acquisition of Validity Sensors, Inc., or Validity, we entered into a contingent consideration arrangement. As of December 31, 2015, we may be required to make additional cash payments of up to \$100.6 million as consideration to the former Validity stockholders and option holders based on unit sales of products utilizing Validity technology through March 2016.

In connection with our acquisition of Pacinian Corporation, or Pacinian, we entered into a contingent consideration arrangement. As of December 31, 2015, we may be required to make additional cash payments of up to \$10.0 million as consideration to the former Pacinian stockholders based on unit sales of products utilizing ThinTouch technology through June 2016.

Changes in the fair value of our contingent consideration liabilities subsequent to the Validity and Pacinian acquisitions are included in operating expenses as change in contingent consideration in the condensed consolidated statements of income. Cash payments of contingent consideration are classified in the condensed consolidated statements of cash flows as a financing activity up to the amount of the contingent consideration recorded at the time

of the acquisition, and as an operating activity for cash payments that exceed the liability recorded at the time of acquisition.

There were no transfers in or out of our Level 1, 2, or 3 assets or liabilities during the three and six months ended December 31, 2015 and 2014.

The fair values of our accounts receivable and accounts payable approximate their carrying values because of the short-term nature of those instruments. Intangible assets, property and equipment, and goodwill are measured at fair value on a non-recurring basis if impairment is indicated. The interest rate on our bank debt is variable, which is subject to change from time to time to reflect a market interest rate; accordingly, the carrying value of our bank debt approximates fair value.

#### 5. Auction Rate Securities

Our ARS investments, which are primarily included in non-current other assets in the condensed consolidated balance sheets, have failed to settle in auctions beginning in 2007. These investments are not liquid, and in the event we need to access these funds, we will not be able to do so without a loss of principal, unless redeemed by the issuers or a future auction on these investments is successful. During the six months ended December 31, 2015, \$0.6 million of our ARS investments were redeemed at par value.

As there are currently no active markets for our various failed ARS investments, we have estimated the fair value of these investments as of December 31, 2015 using a trinomial discounted cash flow analysis. The analysis considered, among others, the following factors:

- the collateral underlying the security investments;
- the creditworthiness of the counterparty;
- the timing of expected future cash flows;
- the probability of a successful auction in a future period;
- the underlying structure of each investment;
- the present value of future principal and interest payments discounted at rates considered to reflect current market conditions;
- a consideration of the probabilities of default, a successful future auction, or redemption at par for each period; and
- estimates of the recovery rates in the event of default for each investment.

When possible, our failed ARS investments were compared to other observable market data or securities with similar characteristics. Our estimate of the fair value of our ARS investments could fluctuate from period to period depending on future market conditions.

We have ARS investments with a fair value of \$12.4 million maturing in fiscal year 2018 and \$1.8 million fair value with no maturity date. As of December 31, 2015, all of our ARS investments are below investment grade.

The various types of ARS investments we held as of December 31, 2015, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain, and fair value, consisted of the following (in millions):

|                     | Original<br>Cost<br>Basis | Other-than-<br>temporary<br>Impairment<br>in<br>Retained<br>Earnings |     | New<br>Cost<br>Basis | Unrealized<br>Gain | Fair<br>Value  |
|---------------------|---------------------------|--|-----|----------------------|--------------------|----------------|
| Credit linked notes | \$ 13.5                   | \$ (5.2 )  | (1) | \$ 8.3               | \$ 4.1             | \$ 12.4        |
| Preferred stock     | 5.0                       | (5.0 )   |     | -                    | 1.8                | 1.8            |
| <b>Total ARS</b>    | <b>\$ 18.5</b>            | <b>\$ (10.2 )</b>  |     | <b>\$ 8.3</b>        | <b>\$ 5.9</b>      | <b>\$ 14.2</b> |

(1) Other-than-temporary impairment in retained earnings is partially offset by cumulative accretion of \$3.1 million on non-current investments. Accretion is reclassified from accumulated other comprehensive income and recorded in the condensed consolidated statements of income as non-cash interest income.

The various types of ARS investments we held as of June 30, 2015, including the original cost basis, other-than-temporary impairment included in retained earnings, new cost basis, unrealized gain, and fair value, consisted of the following (in millions):



|                     | Other-than-    |                          |               | Impairment    |                |  |
|---------------------|----------------|--------------------------|---------------|---------------|----------------|--|
|                     | temporary      |                          |               | in            |                |  |
|                     | Original       | Retained                 | New           | Unrealized    | Fair           |  |
|                     | Cost           | Earnings                 | Cost          | Gain          | Value          |  |
|                     | Basis          |                          | Basis         |               |                |  |
| Credit linked notes | \$ 13.5        | \$ (6.1 ) <sup>(1)</sup> | \$ 7.4        | \$ 5.0        | \$ 12.4        |  |
| Preferred stock     | 5.0            | (5.0 )                   | -             | 2.8           | 2.8            |  |
| Municipals          | 0.6            | (0.1 )                   | 0.5           | 0.1           | 0.6            |  |
| <b>Total ARS</b>    | <b>\$ 19.1</b> | <b>\$ (11.2 )</b>        | <b>\$ 7.9</b> | <b>\$ 7.9</b> | <b>\$ 15.8</b> |  |

(1) Other-than-temporary impairment in retained earnings is partially offset by cumulative accretion of \$2.7 million on non-current investments. Accretion is reclassified from accumulated other comprehensive income and recorded in the condensed consolidated statements of income as non-cash interest income.

All of our ARS investments are accounted for as non-current as the maturity dates are more than 12 months from the balance sheet date. We do not intend to sell the ARS investments before the recovery of the amortized cost basis and it is not more likely than not that we will be required to sell the investments before the recovery of the amortized cost basis.

## 6. Inventories

Inventories are stated at the lower of cost (first-in, first-out method) or market (estimated net realizable value) and consisted of the following (in millions):

|                | December<br>31,<br>2015 | June<br>30,<br>2015 |
|----------------|-------------------------|---------------------|
| Raw materials  | \$ 68.4                 | \$75.5              |
| Finished goods | 68.2                    | 64.7                |
|                | \$ 136.6                | \$140.2             |

We record a liability for estimated probable losses on inventory purchase commitments.

## 7. Acquired Intangibles

The following table summarizes the life, the gross carrying value and the related accumulated amortization of our acquired intangible assets as of December 31, 2015 and June 30, 2015 (in millions):

|                                       | Weighted Average  |                   |               |
|---------------------------------------|-------------------|-------------------|---------------|
|                                       | Life in Years     |                   |               |
|                                       | December 31, 2015 | December 31, 2015 | June 30, 2015 |
| Display driver technology             | 5.3               | \$ 164.0          | \$164.0       |
| Fingerprint authentication technology | 3.6               | 75.6              | 75.6          |
| ThinTouch technology                  | 7.0               | 8.9               | 8.9           |
| Customer relationships                | 2.8               | 48.4              | 48.4          |
| Licensed technology and other         | 5.0               | 1.3               | 1.3           |
| Backlog                               | -                 | -                 | 10.3          |
| Patents                               | 7.9               | 4.5               | 0.1           |

Edgar Filing: SYNAPTICS Inc - Form 10-Q

|                             |     |          |         |
|-----------------------------|-----|----------|---------|
| Supplier arrangement        | 1.8 | 22.0     | 22.0    |
| Acquired intangibles, gross | 4.3 | 324.7    | 330.6   |
| Accumulated amortization    |     | (122.8 ) | (95.2 ) |
| Acquired intangibles, net   |     | \$ 201.9 | \$235.4 |

The total amortization expense for the acquired intangible assets was \$18.8 million and \$46.6 million for the three months ended December 31, 2015 and 2014, respectively, and \$37.9 million and \$47.9 million for the six months ended December 31, 2015 and 2014, respectively. Amortization expense was included in our condensed consolidated statements of income in cost of revenue and acquired intangibles amortization.

The following table presents expected annual fiscal year aggregate amortization expense as of December 31, 2015 (in millions):

|                     |         |
|---------------------|---------|
| Remainder of 2016   | \$35.4  |
| 2017                | 61.2    |
| 2018                | 49.8    |
| 2019                | 35.4    |
| 2020                | 11.9    |
| 2021                | 3.9     |
| Thereafter          | 4.3     |
| Future amortization | \$201.9 |

## 8. Other Accrued Liabilities

Other accrued liabilities consisted of the following (in millions):

|                       | December<br>31,<br>2015 | June<br>30,<br>2015 |
|-----------------------|-------------------------|---------------------|
| Customer obligations  | \$ 41.4                 | \$36.9              |
| Inventory obligations | 16.6                    | 17.2                |
| Warranty              | 3.5                     | 2.8                 |
| Other                 | 15.6                    | 17.2                |
|                       | \$ 77.1                 | \$74.1              |

## 9. Product Warranties, Indemnifications, Contingencies and Legal Proceedings

### Product Warranties

We generally warrant our products for a period of 12 months from the date of delivery and accrue estimated probable product warranty costs as a cost of revenue at the time we recognize revenue. Factors that affect our warranty liability include historical and anticipated rates of warranty claims, materials usage, rework, and delivery costs. We assess the adequacy of our warranty obligations each reporting period and adjust the accrued warranty liability on the basis of our estimates.

### Indemnifications

In connection with certain agreements, we are obligated to indemnify the counterparty against third party claims alleging infringement of certain intellectual property rights by us. We have also entered into indemnification agreements with our officers and directors. Maximum potential future payments cannot be estimated because these agreements do not have a maximum stated liability. However, historical costs related to these indemnification provisions have not been significant. We have not recorded any liability in our condensed consolidated financial statements for such indemnification obligations.

### Contingencies

We have in the past and may in the future receive notices from third parties that claim our products infringe their intellectual property rights. We cannot be certain that our technologies and products do not and will not infringe issued patents or other proprietary rights of third parties.

Any infringement claims, with or without merit, could result in significant litigation costs and diversion of management and financial resources, including the payment of damages, which could have a material adverse effect on our business, financial condition, and results of operations.

### Legal Proceedings

In April 2015, we filed patent infringement actions with the United States District Court in the Northern District of California and with the United States International Trade Commission in which we allege certain competitor products infringe several of our patents. We intend to vigorously pursue these claims.

In October 2015, Amkor Technology filed a complaint against us alleging infringement of intellectual property rights and various other claims. In November 2015, we filed an indemnification claim against the former stockholders and option holders of Validity to secure our rights under the Agreement and Plan of Reorganization between us and Validity. Pursuant to the Agreement, we can offset costs, damages and settlements against the contingent consideration earnout balance for certain of the claims brought by Amkor. Accordingly, we intend to reserve the majority of the remaining contingent consideration earnout balance and have reclassified the reserved balance from a current liability to a non-current liability, as final settlement of the Amkor complaint is not expected to occur within the next twelve months.

We are involved in several other non-material litigation activities. We have expensed all legal fees incurred to date in connection with our legal activities.

## 10. Debt

We have a credit agreement, or the Credit Agreement, in place with the lenders party thereto, or the Lenders, and Wells Fargo Bank, National Association, or the Administrative Agent, as administrative agent for the Lenders.

The Credit Agreement provides for, among other things, (i) a revolving credit facility of up to \$250 million, which includes a \$20 million sublimit for letters of credit and a \$20 million sublimit for swingline loans, and (ii) a term loan facility in an amount of \$150 million. Under the terms of the Credit Agreement, we may, subject to the satisfaction of certain conditions, request increases in the revolving credit facility commitments and additional term loan commitments in an aggregate principal amount of up to \$100 million to the extent existing or new lenders agree to provide such increased or additional commitments, as applicable. We borrowed \$150 million under the term loan facility and \$100 million under the revolving credit facility. Initial debt issuance costs were approximately \$5.0 million, which are being amortized over 60 months.

Our obligations under the Credit Agreement are guaranteed by the material domestic subsidiaries of our company, subject to certain exceptions (such material subsidiaries, together with our company, collectively, the Credit Parties). The obligations of the Credit Parties under the Credit Agreement and the other loan documents delivered in connection therewith are secured by a first priority security interest in substantially all of the existing and future personal property of the Credit Parties, including, without limitation, 65% of the voting capital stock of certain of the Credit Parties' direct foreign subsidiaries, subject to certain exceptions.

The revolving credit facility and term loans bear interest at our election of a Base Rate plus an applicable margin or LIBOR plus an applicable margin. Swingline loans bear interest at a Base Rate plus an applicable margin. The Base Rate is a floating rate that is the greater of the Prime Rate, the Federal Funds Rate plus 50 basis points, or LIBOR plus 100 basis points. The applicable margin is based on a sliding scale which ranges from zero to 100 basis points for Base Rate loans and 100 basis points to 200 basis points for LIBOR loans.

The term loan facility requires repayment over five years with nineteen quarterly principal payments which began in the three months ending March 31, 2015. Each of the first four quarterly principal payments is \$1.9 million, each of the following quarterly principal payments is \$3.8 million, with the final principal payment of \$90.0 million due on September 30, 2019. The revolving credit facility requires payment in full at the end of five years on September 30, 2019. We are also required to pay a commitment fee for any unused portion of the revolving credit facility, which ranges from 0.25% to 0.45% per annum. Interest on the term loan facility and revolving credit facility is payable quarterly. As of December 31, 2015, the outstanding balance of the debt owed under the Credit Agreement was \$242.5 million. On October 20, 2015, we entered into a Commitment Increase Agreement and First Amendment to Credit Agreement, or the First Amendment, with the Administrative Agent and each of the Lenders, which amends the Credit Agreement.

Pursuant to the First Amendment, we exercised our right under the Credit Agreement to request a \$100 million increase to the aggregate revolving credit commitment thereunder, for total aggregate revolving credit commitments of \$250 million and the Lenders under the Credit Agreement agreed to provide such increased revolving credit.

The First Amendment also amends the Credit Agreement by (i) reducing commitment fee rates set forth in the definition of Applicable Margin; (ii) providing that we may, from time to time, request incremental increases from the Lenders in the aggregate revolving and term commitments by an amount not exceeding \$100 million, such increases to be in addition to the increase provided by the First Amendment; and (iii) making certain other administrative changes, all as set forth in the First Amendment.

Borrowings under the Credit Agreement will continue to bear interest at a variable interest rate based on LIBOR or a Base Rate, in each case plus the Applicable Margin. The Applicable Margin is based on our consolidated total leverage ratio pursuant to a pricing grid set forth in the Credit Agreement.

Under the Credit Agreement, there are restrictive operating covenants, including three financial covenants which limit the consolidated total leverage ratio, or leverage ratio, the consolidated interest coverage ratio, or interest coverage ratio, and places a restriction on the amount of capital expenditures that may be made in any fiscal year. The leverage ratio is the ratio of debt as of the measurement date to earnings before interest, taxes, depreciation and amortization, or EBITDA, for the four consecutive quarters ending with the quarter of measurement. The leverage ratio must not exceed 2.50 to 1.0 during the first two years of the agreement, and 2.0 to 1.0 during the last three years of the agreement. The interest coverage ratio is EBITDA to interest expense for the four consecutive quarters ending with the quarter of measurement. The interest coverage ratio must not be less than 3.50 to 1.0 during the term of the Credit Agreement. As of December 31, 2015, we were in compliance with the restrictive operating covenants.

## 11. Share-Based Compensation

Share-based compensation and the related tax benefit recognized in our condensed consolidated statements of income were as follows (in millions):

|  | Three<br>Months<br>Ended<br>December<br>31, |               | Six Months<br>Ended<br>December<br>31, |               |
|--|---|---------------|--|---------------|
|  | 2015  | 2014          | 2015                                   | 2014          |
| Cost of revenue                                | \$0.4                                       | \$0.3         | \$0.8                                  | \$0.6         |
| Research and development                       | 7.5   | 6.0           | 14.0                                   | 11.4          |
| Selling, general, and administrative           | 6.1   | 4.4           | 11.1                                   | 8.2           |
| <b>Total</b>                                   | <b>\$14.0</b>                               | <b>\$10.7</b> | <b>\$25.9</b>                          | <b>\$20.2</b> |
| Income tax benefit on share-based compensation | \$3.9                                       | \$3.0         | \$6.8                                  | \$5.7         |

Historically, we have issued new shares in connection with our share-based compensation plans, however, treasury shares were also available for issuance as of December 31, 2015. Any additional shares repurchased under our common stock repurchase program would be available for issuance under our share-based compensation plans.

## Stock Options

Stock option activity, including stock options granted, exercised, and forfeited, weighted average exercise prices for stock options outstanding and exercisable, and the aggregate intrinsic value were as follows:

|                                  | Stock<br>Option<br>Awards | Weighted<br>Average<br>Exercise<br>Price | Aggregate<br>Intrinsic<br>Value<br>(in<br>millions) |
|----------------------------------|---------------------------|--|---|
|                                  | Outstanding               |  |   |
| Balance as of June 30, 2015      | 2,870,425                 | \$ 38.50                                 |   |
| Granted                          | 239,840                   | 84.34                                    |   |
| Exercised                        | (402,408 )                | 29.40                                    |   |
| Forfeited                        | (4,265 )                  | 74.00                                    |   |
| Balance as of December 31, 2015  | 2,703,592                 | 43.86                                    | \$ 102.5  |
| Exercisable at December 31, 2015 | 1,912,867                 | 31.69                                    | \$ 94.4   |

The aggregate intrinsic value was determined using the closing price of our common stock on December 24, 2015 of \$81.00 and excludes the impact of stock options that were not in-the-money.

## Deferred Stock Units

DSU activity, including DSUs granted, delivered, and forfeited, and the balance and aggregate intrinsic value of DSUs was as follows:



Edgar Filing: SYNAPTICS Inc - Form 10-Q

|                                 | DSU<br>Awards | Aggregate<br>Intrinsic<br>Value<br>(in<br>millions) |
|---------------------------------|---------------|---|
| Balance as of June 30, 2015     | 860,376       |   |
| Granted                         | 579,618       |   |
| Delivered                       | (269,344 )    |   |
| Forfeited                       | (26,070 )     |   |
| Balance as of December 31, 2015 | 1,144,580     | \$ 92.7   |

The aggregate intrinsic value was determined using the closing price of our common stock on December 24, 2015 of \$81.00.

Of the shares delivered, 76,767 shares valued at \$6.4 million were withheld to meet statutory minimum tax withholding requirements.

## Market Stock Units

Our Amended and Restated 2010 Incentive Compensation Plan provides for the grant of MSU awards to our employees, consultants, and directors. An MSU is a promise to deliver shares of our common stock at a future date based on the achievement of market-based performance requirements in accordance with the terms of the MSU grant agreement.

We have granted MSUs to our executive officers, which are designed to vest in three tranches with the target quantity for each tranche equal to one-third of the total MSU grant. The first tranche vests based on a one-year performance period; the second tranche vests based on a two-year performance period; and the third tranche vests based on a three-year performance period. Performance is measured based on the achievement of a specified level of total stockholder return, or TSR, relative to the TSR of the Philadelphia Semiconductor Index, or SOX Index. The potential payout ranges from 0% to 200% of the grant target quantity and is adjusted on a two-to-one ratio based on our TSR performance relative to the SOX Index TSR performance using the following formula:

$$(100\% + ([\text{Synaptics TSR} - \text{SOX Index TSR}] \times 2))$$

Beginning with the MSU grants in fiscal 2015, the payout for tranche one and two will not exceed 100% and the payout for tranche three will be calculated based on the total target quantity for the entire grant multiplied by the payout factor, which will then be reduced by tranche one and tranche two stock issuances.

Delivery of shares earned, if any, will take place on the dates provided in the applicable MSU grant agreement, assuming the grantee is still an employee, consultant, or director of our company at the end of the applicable performance period. On the delivery date, we withhold shares to cover statutory minimum tax withholding requirements and deliver a net quantity of shares to the employee, consultant, or director after such withholding. Until delivery of shares, the grantee has no rights as a stockholder with respect to any shares underlying the MSU award.

During the six months ended December 31, 2015, MSU activity, including MSUs granted, delivered, and forfeited, and the balance and aggregate intrinsic value of MSUs as of December 31, 2015 was as follows:

|                                 | MSU<br>Awards | Aggregate<br>Intrinsic<br>Value<br>(in<br>millions) |
|---------------------------------|---------------|---|
|                                 | Outstanding   |   |
| Balance as of June 30, 2015     | 132,376       |   |
| Granted                         | 77,700        |   |
| Performance adjustment          | 41,921        |   |
| Delivered                       | (103,199 )    |   |
| Forfeited                       | (2,648 )      |   |
| Balance as of December 31, 2015 | 146,150       | \$ 11.8   |

We value the MSUs using the Monte Carlo simulation model on the date of grant and amortize the compensation expense over the three-year performance and service period on a straight-line basis. The unrecognized share-based compensation cost of our outstanding MSUs was approximately \$13.2 million as of December 31, 2015, which will be recognized over a weighted average period of approximately 1.44 years.

## 12. Income Taxes

We account for income taxes under the asset and liability method. We consider the operating earnings of our foreign subsidiaries to be indefinitely invested outside the United States. Therefore, no provision has been made for the federal, state, or foreign taxes that may result from future remittances of undistributed earnings of our foreign subsidiaries.

The provision for income taxes recorded in interim periods is recorded by applying the estimated annual effective tax rate to year-to-date income before provision for income taxes, excluding the effects of significant unusual or infrequently occurring discrete items. The tax effects of discrete items are recorded in the same period that the related discrete items are reported and results in a difference between the actual effective tax rate and the estimated annual effective tax rate.

The provision for income taxes of \$9.5 million and \$8.3 million for the three months ended December 31, 2015 and 2014, respectively, represented estimated federal, state, and foreign income taxes. The effective tax rate for the three months ended December 31, 2015 and 2014, diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates and research credits, which included the retroactive reinstatement of the federal research credit, partially offset by foreign withholding taxes, nondeductible amortization, and net unrecognized tax benefits associated with qualified

stock options. Federal research and development credits of \$3.1 million generated from fiscal 2015 were treated as a discrete tax benefit in the three months ended December 31, 2015. The provision for income taxes for the three months ended December 31, 2014, excluding the impact of accounting for contingent consideration as a discrete item, would have been \$9.2 million.

The provision for income taxes of \$18.7 million and \$18.6 million for the six months ended December 31, 2015 and 2014, respectively, represented estimated federal, state, and foreign income taxes. The effective tax rate for the six months ended December 31, 2015 diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates and research credits, partially offset by foreign withholding taxes, nondeductible amortization and net unrecognized tax benefits associated with qualified stock options. Federal research and development credits of \$3.1 million generated from fiscal 2015 were treated as a discrete tax benefit in the six months ended December 31, 2015. The effective tax rate for the six months ended December 31, 2014 diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates, partially offset by foreign withholding taxes, nondeductible amortization, and net unrecognized tax benefits associated with qualified stock options. The provision for income taxes for the six months ended December 31, 2014, excluding the impact of accounting for contingent consideration as a discrete item, would have been \$20.5 million.

On March 31, 2015, Japan's parliament approved legislation to reduce corporate income tax rates by 3.29 percentage points over the next two years. As a result, the current combined national and local effective tax rate of 35.6% will be reduced to 32.3% over the next two years. We accounted for the impact of the tax rate change in the fourth quarter of our fiscal 2015.

The Protecting Americans from Tax Hikes Act of 2015, or the PATH Act which made research tax credit permanent, was passed on December 17, 2015. The PATH Act retroactively extended federal research credit from January 1, 2015. As such, we recognized six months of tax benefit totaling \$3.1 million from the federal research tax credit related to fiscal 2015 and another six months of federal research tax credit in the second quarter of fiscal 2016.

The total liability for gross unrecognized tax benefits related to uncertain tax positions increased \$2.3 million during the six months ended December 31, 2015 to \$13.9 million from \$11.6 million at June 30, 2015, and was included in other long-term liabilities on our condensed consolidated balance sheets. If recognized, the total gross unrecognized tax benefits would reduce the effective tax rate on income from continuing operations. Accrued interest and penalties related to unrecognized tax benefits as of December 31, 2015 was \$1.4 million; this balance increased by \$0.3 million from June 30, 2015. We classify interest and penalties as components of income tax expense. It is reasonably possible that the amount of the liability for unrecognized tax benefits may change within the next twelve months and an estimate of the range of possible changes is an increase in our liability up to \$1.0 million.

In July 2015, the U.S. Tax Court issued an opinion in *Altera Corp. v. Commissioner* related to a treasury regulation addressing the treatment of stock-based compensation in a cost-sharing arrangement with a related party. At this time, a final decision has not been issued by the U.S. Tax Court. Further, the U.S. Department of the Treasury has not withdrawn the requirement in its regulations related to the treatment of stock-based compensation. The Commissioner has the right to appeal the U.S. Tax Court decision. While we determined no adjustment to our financial statements is required due to the uncertainties with respect to the ultimate resolution, we will continue to monitor developments in this case.

In September 2015, we were notified by the National Tax Agency of Japan that our open tax years would be subject to audit.

Our major tax jurisdictions are the United States, Hong Kong SAR, and Japan. From fiscal 2009 onward, we remain subject to examination by one or more of these jurisdictions.

### 13. Segment, Customers, and Geographic Information

We operate in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. We generate our revenue from two broad product categories: the mobile product market and the personal computing, or PC, product market. We sell our products to original equipment manufacturers, or OEMs, and to contract manufacturers that provide manufacturing services to OEMs.

16

---

Edgar Filing: SYNAPTICS Inc - Form 10-Q

Net revenue within geographic areas based on our customers' locations for the periods presented was as follows (in millions):

|               | Three Months Ended December 31, 2015 <sup>(1)</sup> |                     | Six Months Ended December 31, 2015 <sup>(1)</sup> |                     |
|---------------|---|---------------------|---|---------------------|
|               | 2014 <sup>(1)</sup>                                 | 2015 <sup>(1)</sup> | 2014 <sup>(1)</sup>                               | 2015 <sup>(1)</sup> |
| Japan         | \$231.3   | \$242.9             | \$237.0   | \$472.0             |
| China         | 126.3   | 128.0               | 274.5   | 233.8               |
| United States | 37.5  | 47.0                | 78.3  | 113.0               |
| South Korea   | 32.0  | 37.2                | 78.8  | 88.2                |
| Taiwan        | 32.2  | 15.2                | 68.4  | 33.1                |
| Other         | 4.4   | 0.2                 | 9.5   | 0.4                 |
|               | \$463.7   | \$470.5             | \$746.5   | \$940.5             |

(1) Includes the results of operations from RSP, which was acquired on October 1, 2014.

Net revenue from our customers for each group of similar products was as follows (in millions):

|                             | Three Months Ended December 31, 2015 <sup>(1)</sup> |                     | Six Months Ended December 31, 2015 <sup>(1)</sup> |                     |
|-----------------------------|---|---------------------|---|---------------------|
|                             | 2014 <sup>(1)</sup>                                 | 2015 <sup>(1)</sup> | 2014 <sup>(1)</sup>                               | 2015 <sup>(1)</sup> |
| Mobile product applications | \$398.3   | \$407.8             | \$598.1   | \$819.9             |
| PC product applications     | 65.4  | 62.7                | 148.4   | 120.6               |
|                             | \$463.7   | \$470.5             | \$746.5   | \$940.5             |

(1) Includes the results of operations from RSP, which was acquired on October 1, 2014.

Net revenue from major customers as a percentage of total net revenue for the periods presented was as follows:

|            | Three Months Ended December 31, 2015 |      | Six Months Ended December 31, 2015 |      |
|------------|--------------------------------------|------|------------------------------------|------|
|            | 2014                                 | 2015 | 2014                               | 2015 |
| Customer A | 24%                                  | 22%  | 15%                                | 21%  |
| Customer B | 13%                                  | 16%  | 17%                                | 19%  |

Edgar Filing: SYNAPTICS Inc - Form 10-Q

|            |     |     |     |   |
|------------|-----|-----|-----|---|
| Customer C | 16% | 12% | 17% | * |
| Customer D | 12% | 12% | 11% | * |

\*Less than 10%

We extend credit based on evaluation of a customer's financial condition, and we generally do not require collateral. Major customer accounts receivable as a percentage of total accounts receivable were as follows:

|            | December<br>31,<br>2015 | June<br>30,<br>2015 |
|------------|-------------------------|---------------------|
| Customer A | 20%                     | 20%                 |
| Customer B | 20%                     | 13%                 |
| Customer C | 13%                     | 13%                 |
| Customer D | 12%                     | 13%                 |

#### 14. Comprehensive Income

Our comprehensive income generally consists of net income plus the effect of unrealized gains and losses on our investments, primarily due to temporary changes in market value of certain of our ARS investments. In addition, we recognize the noncredit portion of other-than-temporary impairment on debt securities in other comprehensive income. We recognize foreign currency remeasurement adjustments and transaction gains and losses in our condensed consolidated statements of income as the U.S. dollar is the functional currency of our foreign entities.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Forward-Looking Statements and Factors That May Affect Results

This Quarterly Report on Form 10-Q for the quarter ended December 26, 2015 (this "Report") contains forward-looking statements that are subject to the safe harbors created under the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Act of 1934, as amended (the "Exchange Act"). For ease of presentation, this Report shows reporting periods ending on calendar quarter end dates as of and for all periods presented, unless otherwise indicated. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business, and can be identified by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements may include words such as "expect," "anticipate," "intend," "believe," "estimate," "plan," "target," "strategy," "continue," "may," "will," "should," variations of such words, or other words and terms of similar meaning. All forward-looking statements reflect our best judgment and are based on several factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Such factors include, but are not limited to, the risks as identified in the "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Business" sections of our Annual Report on Form 10-K for the fiscal year ended June 27, 2015, and other risks as identified from time to time in our SEC reports. Forward-looking statements are based on information available to us on the date hereof, and we do not have, and expressly disclaim, any obligation to publicly release any updates or any changes in our expectations, or any change in events, conditions, or circumstances on which any forward-looking statement is based. Our actual results and the timing of certain events could differ materially from the forward-looking statements. These forward-looking statements do not reflect the potential impact of any mergers, acquisitions, or other business combinations that had not been completed as of the date of this filing.

Statements made in this Report, unless the context otherwise requires, include the use of the terms "us," "we," "our," the "Company" and "Synaptics" to refer to Synaptics Incorporated and its consolidated subsidiaries.

### Overview

We are a leading worldwide developer and supplier of custom-designed human interface semiconductor product solutions that enable people to interact more easily and intuitively with a wide variety of mobile computing, communications, entertainment, and other electronic devices. We believe our results to date reflect the combination of our customer focus, the strength of our intellectual property, and our engineering know-how, which allow us to develop and engineer products that meet the demanding design specifications of OEMs.

Many of our customers have manufacturing operations in China, and many of our OEM customers have established design centers in Asia. With our expanding global presence, including offices in Armenia, China, Finland, Hong Kong, India, Japan, Korea, Switzerland, Taiwan, and the United States, we are well positioned to provide local sales, operational, and engineering support services to our existing customers, as well as potential new customers, on a global basis.

Our manufacturing operations are based on a variable cost model in which we outsource all of our production requirements and generally drop ship our products directly to our customers from our contract manufacturers' facilities, thereby reducing the need for significant capital expenditures and allowing us to minimize our investment in inventories. This approach requires us to work closely with our contract manufacturers and semiconductor foundries to ensure adequate production capacity to meet our forecasted volume requirements. We provide our contract manufacturers with six-month rolling forecasts and issue purchase orders based on our anticipated requirements for the next 90 days. However, we do not have long-term supply contracts with any of our contract manufacturers. We use



third-party wafer manufacturers to supply wafers and third-party packaging manufacturers to package our proprietary ASICs. In certain cases, we rely on a single source or a limited number of suppliers to provide other key components of our products. Our cost of revenue includes all costs associated with the production of our products, including materials; logistics; amortization of intangibles related to acquired developed technology, backlog, and supplier arrangements; manufacturing, assembly, and test costs paid to third-party manufacturers; and related overhead costs associated with our indirect manufacturing operations personnel. Additionally, we charge all warranty costs, losses on inventory purchase obligations, and write-downs to reduce the carrying value of obsolete, slow moving, and non-usable inventory to net realizable value to cost of revenue.

Our gross margin generally reflects the combination of the added value we bring to our OEM customers' products by meeting their custom design requirements and the impact of our ongoing cost-improvement programs. These cost-improvement programs include reducing materials and component costs, and implementing design and process improvements. Our newly introduced products may have lower margins than our more mature products, which have realized greater benefits associated with our ongoing cost-improvement programs. As a result, new product introductions may initially negatively impact our gross margin.

Our research and development expenses include costs for supplies and materials related to product development as well as the engineering costs incurred to design ASICs and human interface solutions for OEM customers prior to and after their commitment to

incorporate those solutions into their products. These expenses have generally increased, reflecting our continuing commitment to the technological and design innovation required to maintain our position in our existing markets, and to adapt our existing technologies or develop new technologies for new markets.

Selling, general, and administrative expenses include expenses related to sales, marketing, and administrative personnel; internal sales and outside sales representatives' commissions; market and usability research; outside legal, accounting, and consulting costs; and other marketing and sales activities. These expenses have generally increased, primarily reflecting incremental staffing and related support costs associated with our business acquisitions, increased business levels, growth in our existing markets, and penetration into new markets.

Restructuring costs include severance costs related to restructuring of the operations related to our acquisition of RSP.

Change in contingent consideration is a cost associated with the acquisition of a business in which an earn-out arrangement is entered into between us and a selling party. We entered into earn-out arrangements in connection with our acquisitions of both Pacinian and Validity. The earn-out arrangements were designed to deliver more purchase price consideration to the selling parties, provided the acquired business delivers on the negotiated earn-out terms. As both of these earn-out arrangements are near the end of their respective earn-out periods, we anticipate substantially less volatility in our estimate of contingent consideration through the remainder of fiscal 2016.

#### Critical Accounting Policies and Estimates

There have been no significant changes in our critical accounting policies and estimates during the six months ended December 31, 2015, compared with our critical accounting policies and estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended June 27, 2015.

#### Results of Operations

Certain of the data used in our condensed consolidated statements of income for the periods indicated, together with comparative absolute and percentage changes in these amounts, were as follows (in millions, except percentages):

|                                      | Three Months Ended December 31, |                     |        |                   |  | Six Months Ended December 31, |                     |          |                   |  |
|--------------------------------------|---------------------------------|---------------------|--------|-------------------|--|-------------------------------|---------------------|----------|-------------------|--|
|                                      | 2015 <sup>(1)</sup>             | 2014 <sup>(1)</sup> | \$     | %                 |  | 2015 <sup>(1)</sup>           | 2014 <sup>(1)</sup> | \$       | %                 |  |
|                                      |                                 |                     | Change | Change            |  |                               |                     | Change   | Change            |  |
| Mobile product applications          | \$407.8                         | \$398.3             | \$ 9.5 | 2.4 %             |  | \$819.9                       | \$598.1             | \$ 221.8 | 37.1 %            |  |
| PC product applications              | 62.7                            | 65.4                | (2.7 ) | (4.1 %)           |  | 120.6                         | 148.4               | (27.8 )  | (18.7 %)          |  |
| Net revenue                          | 470.5                           | 463.7               | 6.8    | 1.5 %             |  | 940.5                         | 746.5               | 194.0    | 26.0 %            |  |
| Gross margin                         | 165.2                           | 126.8               | 38.4   | 30.3 %            |  | 329.0                         | 247.1               | 81.9     | 33.1 %            |  |
| Operating expenses:                  |                                 |                     |        |                   |  |                               |                     |          |                   |  |
| Research and development             | 78.6                            | 77.3                | 1.3    | 1.7 %             |  | 159.1                         | 134.8               | 24.3     | 18.0 %            |  |
| Selling, general, and administrative | 41.0                            | 22.0                | 19.0   | 86.4 %            |  | 81.2                          | 52.7                | 28.5     | 54.1 %            |  |
| Acquired intangibles amortization    | 4.6                             | 4.6                 | -      | 0.0 %             |  | 9.3                           | 4.9                 | 4.4      | 89.8 %            |  |
| Change in contingent consideration   | (4.3 )                          | (7.1 )              | 2.8    | 39.4 %            |  | (1.6 )                        | (11.6 )             | 10.0     | 86.2 %            |  |
| Restructuring costs                  | -                               | -                   | -      | nm <sup>(2)</sup> |  | 1.9                           | -                   | 1.9      | nm <sup>(2)</sup> |  |
| Operating income                     | 45.3                            | 30.0                | 15.3   | 51.0 %            |  | 79.1                          | 66.3                | 12.8     | 19.3 %            |  |
| Interest and other expense, net      | (0.8 )                          | (0.7 )              | (0.1 ) | 14.3 %            |  | (1.6 )                        | (0.1 )              | (1.5 )   | 1500.0 %          |  |

Edgar Filing: SYNAPTICS Inc - Form 10-Q

|  |        |        |         |        |        |        |         |        |
|--|--------|--------|---------|--------|--------|--------|---------|--------|
| Income before provision for income taxes | 44.5   | 29.3   | 15.2    | 51.9 % | 77.5   | 66.2   | 11.3    | 17.1 % |
| Provision for income taxes               | 9.5    | 8.3    | 1.2     | 14.5 % | 18.7   | 18.6   | 0.1     | 0.5 %  |
| Net income                               | \$35.0 | \$21.0 | \$ 14.0 | 66.7 % | \$58.8 | \$47.6 | \$ 11.2 | 23.5 % |

(1) Includes the post-acquisition results of operations of RSP, acquired October 1, 2014.

(2) Not meaningful.

19

---

Certain of the data used in our condensed consolidated statements of income presented here as a percentage of net revenue for the periods indicated were as follows:

|  | Three Months Ended December 31, 2015 <sup>(1)</sup> |                     | Percentage Point Increase/ (Decrease) | Six Months Ended December 31, 2015 <sup>(1)</sup> |                     | Percentage Point Increase/ (Decrease) |
|--|---|---------------------|---------------------------------------|---|---------------------|---------------------------------------|
|  | 2015 <sup>(1)</sup>                                 | 2014 <sup>(1)</sup> |                                       | 2015 <sup>(1)</sup>                               | 2014 <sup>(1)</sup> |                                       |
| Mobile product applications              | 86.7 %  | 85.9 %              | 0.8 %                                 | 87.2 %  | 80.1 %              | 7.1 %                                 |
| PC product applications                  | 13.3 %  | 14.1 %              | (0.8 %)                               | 12.8 %  | 19.9 %              | (7.1 %)                               |
| Net revenue                              | 100.0%  | 100.0 %             | 0.0 %                                 | 100.0%  | 100.0 %             | 0.0 %                                 |
| Gross margin                             | 35.1 %  | 27.3 %              | 7.8 %                                 | 35.0 %  | 33.1 %              | 1.9 %                                 |
| Operating expenses:                      |   |                     |                                       |   |                     |                                       |
| Research and development                 | 16.7 %  | 16.7 %              | 0.0 %                                 | 16.9 %  | 18.1 %              | (1.2 %)                               |
| Selling, general, and administrative     | 8.7 %   | 4.7 %               | 4.0 %                                 | 8.6 %   | 7.1 %               | 1.5 %                                 |
| Acquired intangibles amortization        | 1.0 %   | 1.0 %               | 0.0 %                                 | 1.0 %   | 0.7 %               | 0.3 %                                 |
| Change in contingent consideration       | (0.9 %)   | (1.5 %)             | 0.6 %                                 | (0.2 %)   | (1.6 %)             | 1.4 %                                 |
| Restructuring costs                      | 0.0 %   | 0.0 %               | 0.0 %                                 | 0.2 %   | 0.0 %               | 0.2 %                                 |
| Operating income                         | 9.6 %   | 6.5 %               | 3.1 %                                 | 8.4 %   | 8.9 %               | (0.5 %)                               |
| Interest and other expense, net          | (0.2 %)   | (0.2 %)             | 0.0 %                                 | (0.2 %)   | 0.0 %               | (0.2 %)                               |
| Income before provision for income taxes | 9.5 %   | 6.3 %               | 3.2 %                                 | 8.2 %   | 8.9 %               | (0.7 %)                               |
| Provision for income taxes               | 2.0 %   | 1.8 %               | 0.2 %                                 | 2.0 %   | 2.5 %               | (0.5 %)                               |
| Net income                               | 7.4 %   | 4.5 %               | 2.9 %                                 | 6.3 %   | 6.4 %               | (0.1 %)                               |

(1) Includes the post-acquisition results of operations of RSP, acquired October 1, 2014.

## Net Revenue

Net revenue was \$470.5 million for the three months ended December 31, 2015 compared with \$463.7 million for the three months ended December 31, 2014, an increase of \$6.8 million, or 1.5%. Of this net revenue, \$407.8 million, or 86.7% was from mobile product applications and \$62.7 million, or 13.3%, was from PC product applications. The increase in net revenue for the three months ended December 31, 2015 was attributable to an increase in net revenue from mobile product applications. Net revenue from mobile product applications increased as a result of slightly higher average selling prices, primarily due to product mix. Net revenue from PC product applications decreased primarily as a result of lower unit sales.

Net revenue was \$940.5 million for the six months ended December 31, 2015 compared with \$746.5 million for the six months ended December 31, 2014, an increase of \$194.0 million, or 26.0%. Of this net revenue, \$819.9 million, or 87.2% was from mobile product applications and \$120.6 million, or 12.8%, was from PC product applications. The increase in net revenue for the six months ended December 31, 2015 was attributable to an increase in net revenue from mobile product applications. Net revenue from mobile product applications increased as a result of higher unit sales, primarily due to sales of display driver integrated circuits, or DDIC products, acquired as a result of our acquisition of RSP in October 2014. Net revenue from PC product applications decreased primarily as a result of lower unit sales.

Based on industry estimates of unit shipments, the smartphone market is anticipated to increase approximately 7.7%; the tablet market is anticipated to decline approximately 2.2%; the detachable tablets market within the general tablet market is expected to grow at 76.2%; the notebook market is anticipated to decrease approximately 1.5%; and the wearable market within the mobile market is expected to increase 44.4% in calendar year 2016 compared with calendar year 2015. Our revenue may differ from the forecasted trends in the markets we serve.

## Gross Margin

Gross margin as a percentage of net revenue was 35.1%, or \$165.2 million, for the three months ended December 31, 2015 compared with 27.3%, or \$126.8 million, for the three months ended December 31, 2014. The 780 basis point increase in gross margin was primarily due to a reduction of acquisition-related amortization costs and higher gross margins on our DDIC products, both directly related to our acquisition of RSP in October 2014.

Gross margin as a percentage of net revenue was 35.0%, or \$329.0 million, for the six months ended December 31, 2015 compared with 33.1%, or \$247.1 million, for the six months ended December 31, 2014. The 190 basis point increase in gross margin was due to a reduction of acquisition-related amortization costs and higher gross margins on our DDIC products, both directly related to our acquisition of RSP in October 2014.

We continually introduce new product solutions, many of which have life cycles of less than one year. Further, as we sell our technology solutions in designs that are generally unique or specific to an OEM customer's application, gross margin varies on a product-by-product basis, making our cumulative gross margin a blend of our product specific designs. As a virtual manufacturer, our gross margin percentage is generally not materially impacted by our shipment volume. We charge losses on inventory purchase obligations and write-down to reduce the carrying value of obsolete, slow moving, and non-usable inventory to net realizable value (including warranty costs) to cost of revenue.

## Operating Expenses

Research and Development Expenses. Research and development expenses increased \$1.3 million to \$78.6 million for the three months ended December 31, 2015 compared with the three months ended December 31, 2014. The increase in research and development expenses primarily reflected a \$2.4 million increase in infrastructure-related costs; a \$1.9

million increase in personnel-related costs, which included our annual merit increase, an increase in share-based compensation costs, and additional headcount associated with an expanded product portfolio; a \$1.2 million increase in supplies and project related costs; partially offset by a \$3.2 million decrease in non-employee services.

Research and development expenses increased \$24.3 million to \$159.1 million for the six months ended December 31, 2015 compared with the six months ended December 31, 2014. The increase in research and development expenses primarily reflected an \$10.2 million increase in personnel-related costs, which included additional headcount related to our acquisition of RSP in October 2014, our annual merit increase, an increase in share-based compensation costs, and additional headcount associated with an expanded product portfolio; a \$9.2 million increase in infrastructure-related costs; a \$3.4 million increase in supplies; and a \$2.6 million increase in software license fees.

Selling, General, and Administrative Expenses. Selling, general, and administrative expenses increased \$19.0 million to \$41.0 million for the three months ended December 31, 2015 compared with the three months ended December 31, 2014. The increase in selling, general, and administrative expenses primarily reflected a \$15.5 million reduction in the foreign currency transaction and remeasurement gains; a \$4.5 million increase in personnel-related costs, related to our annual merit increase, an increase in share-based compensation costs, and additional headcount in our base business; and a \$4.4 million increase in professional fees, primarily related to an increase in legal fees; partially offset by a \$3.6 million decrease in non-employee services.

Selling, general, and administrative expenses increased \$28.5 million to \$81.2 million for the six months ended December 31, 2015 compared with the six months ended December 31, 2014. The increase in selling, general, and administrative expenses primarily reflected a \$16.8 million reduction in the foreign currency transaction and remeasurement gains; an \$11.6 million increase in personnel-related costs, which included additional headcount related to our acquisition of RSP in October 2014, our annual merit increase, an increase in share-based compensation costs, and additional headcount in our base business; and a \$6.0 million increase in legal fees; partially offset by a \$3.1 million decrease in non-employee services.

Acquired intangibles amortization. Acquired intangibles amortization reflects the amortization of intangibles acquired through recent acquisitions. See note 7 to the condensed consolidated financial statements.

Change in Contingent Consideration. Our contingent consideration increased \$2.8 million to a credit of \$4.3 million for the three months ended December 31, 2015 compared with the three months ended December 31, 2014. The change was primarily attributable to the decrease in the estimated fair value of the contingent consideration, which resulted from an adjustment in expected unit sales of products embodying Validity fingerprint authentication technology over the remaining earn-out period ending March 2016.

Our contingent consideration increased \$10.0 million to a credit of \$1.6 million for the six months ended December 31, 2015 compared with the six months ended December 31, 2014. The change was primarily attributable to the decrease in the estimated fair value of the contingent consideration, which resulted from an adjustment in expected unit sales of products embodying Validity fingerprint authentication technology over the remaining earn-out period ending March 2016.

Restructuring costs. Restructuring costs of \$1.9 million in the six months ended December 31, 2015 reflect severance costs related to restructuring of the operations related to the RSP acquisition. These headcount-related costs were primarily in research and development.

Interest and other expense, net. Interest and other expense, net increased as a result of interest expense on the \$250.0 million in debt borrowed in conjunction with our acquisition of RSP in October 2014. See note 10 to the condensed consolidated financial statements.

#### Provision for Income Taxes

We account for income taxes under the asset and liability method. We consider the operating earnings of our foreign subsidiaries to be indefinitely invested outside the United States. Therefore no provision has been made for the federal, state, or foreign taxes that may result from future remittances of undistributed earnings of our foreign subsidiaries.

The provision for income taxes recorded in interim periods is recorded by applying the estimated annual effective tax rate to year-to-date income before provision for income taxes, excluding the effects of significant unusual or infrequently occurring discrete items. The tax effects of discrete items are recorded in the same period that the related

discrete items are reported and results in a difference between the actual effective tax rate and the estimated annual effective tax rate.

The provision for income taxes of \$9.5 million and \$8.3 million for the three months ended December 31, 2015 and 2014, respectively, represented estimated federal, state, and foreign income taxes. The effective tax rate for the three months ended December 31, 2015 and 2014, diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates and research credits, which included the retroactive reinstatement of the federal research credit, partially offset by foreign withholding taxes, nondeductible amortization, and net unrecognized tax benefits associated with qualified stock options. Federal research and development credits of \$3.1 million generated from fiscal 2015 were treated as a discrete tax benefit in the three months ended December 31, 2015. The provision for income taxes for the three months ended December 31, 2014 would have been \$9.2 million if contingent consideration was not treated as a discrete item.

The provision for income taxes of \$18.7 million and \$18.6 million for the six months ended December 31, 2015 and 2014, respectively, represented estimated federal, state, and foreign income taxes. The effective tax rate for the six months ended December 31, 2015 diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates and research credits, which included the retroactive reinstatement of the federal research credit, partially offset by foreign withholding taxes, nondeductible amortization, contingent consideration, and net unrecognized tax benefits associated with qualified



stock options. Federal research and development credits of \$3.1 million generated from fiscal 2015 were treated as a discrete tax benefit in the six months ended December 31, 2015. The effective tax rate for the six months ended September 30, 2014 diverged from the combined U.S. federal and state statutory tax rate primarily because of foreign income taxed at lower tax rates and research credits, partially offset by foreign withholding taxes, nondeductible amortization, and net unrecognized tax benefits associated with qualified stock options. The provision for income taxes for the six months ended December 31, 2014 would have been \$20.5 million if contingent consideration was not treated as a discrete item.

On March 31, 2015 Japan's parliament approved legislation to reduce corporate income tax rates by 3.29 percentage points over the next two years. As a result, the current combined national and local effective tax rate of 35.6% will be reduced to 32.3% over the next two years. We accounted for the impact of the tax rate change in the fourth quarter of our fiscal 2015.

Protecting Americans from Tax Hikes Act of 2015, or the PATH Act which made the federal research tax credit permanent, was passed on December 17, 2015. The PATH Act retroactively extended federal research credit from January 1, 2015. As such, we recognized six months of tax benefit totaling \$3.1 million from the federal research tax credit related to fiscal 2015 and another six months of federal research tax credit in the second quarter of fiscal 2016.

In July 2015, the U.S. Tax Court issued an opinion in *Altera Corp. v. Commissioner* related to a treasury regulation addressing the treatment of stock-based compensation in a cost-sharing arrangement with a related party. At this time, a final decision has not been issued by the U.S. Tax Court. Further, the U.S. Department of the Treasury has not withdrawn the requirement in its regulations related to the treatment of stock-based compensation. The Commissioner has the right to appeal the U.S. Tax Court decision. While we determined no adjustment to our financial statements is required due to the uncertainties with respect to the ultimate resolution, we will continue to monitor developments in this case.

In September 2015, we were notified by the National Tax Agency of Japan that our open tax years would be subject to audit.

#### Liquidity and Capital Resources

Our cash and cash equivalents were \$372.0 million as of December 31, 2015 compared with \$399.9 million as of June 30, 2015, a decrease of \$27.9 million. The decrease primarily reflected the combination of \$125.0 million used to repurchase 1,668,713 shares of our common stock and \$15.1 million used for the purchase of property and equipment; partially offset by \$106.8 million provided by operating cash flows and \$19.5 million in proceeds from issuance of shares. We consider earnings of our foreign subsidiaries indefinitely invested overseas and have made no provision for income or withholding taxes that may result from a future repatriation of those earnings. As of December 31, 2015, \$235.5 million of cash and cash equivalents was held by our foreign subsidiaries. If these funds are needed for our operations in the United States, we would be required to accrue and pay U.S. federal, state, and foreign taxes to repatriate these funds.

**Cash Flows from Operating Activities.** Operating activities during the six months ended December 31, 2015 generated net cash of \$106.8 million compared with \$44.4 million of net cash generated during the six months ended December 31, 2014. For the six months ended December 31, 2015, net cash provided by operating activities was primarily attributable to net income of \$58.8 million, plus adjustments for non-cash charges of \$73.0 million, and a \$25.0 million net change in operating assets and liabilities. The net change in operating assets and liabilities was primarily attributable to a \$17.7 million decrease in accounts payable, a \$12.4 million increase in accounts receivable, a \$9.6

million decrease in acquisition related obligations; and a \$4.6 million decrease in income taxes payable partially offset by an increase of \$7.5 million in accrued compensation, a \$3.6 million decrease in inventory, and a \$3.1 million increase in other accrued liabilities. From June 30, 2015 to December 31, 2015, our days sales outstanding increased from 61 days to 64 days and our annual inventory turns increased slightly from 8 to 9.

**Cash Flows from Investing Activities.** Investing activities during the six months ended December 31, 2015 primarily used net cash of \$15.1 million for purchases of property and equipment and \$4.4 million for the purchase of intangible assets, compared with \$293.8 million net cash used for acquisition of business, net of cash acquired, \$34.3 million for the purchases of property and equipment, partially offset by \$4.9 million in proceeds from sales of non-current investments during the six months ended December 31, 2014.

**Cash Flows from Financing Activities.** Net cash used in financing activities for the six months ended December 31, 2015, was \$116.1 million compared with net cash provided from financing activities of \$162.7 million provided by financing activities for the six months ended December 31, 2014. Net cash used in financing activities for the six months ended December 31, 2015 primarily related to \$125.0 million used to repurchase 1,668,713 shares of our common stock.

**Common Stock Repurchase Program.** As of December 31, 2015, our board has cumulatively authorized \$1.05 billion for our common stock repurchase program, which will expire in October 2017. The program authorizes us to purchase our common stock in the open market or in privately negotiated transactions, depending upon market conditions and other factors. The number of shares

purchased and the timing of purchases is based on the level of our cash balances, general business and market conditions, and other factors, including alternative investment opportunities. Common stock purchased under this program is held as treasury stock. From April 2005 through December 31, 2015, we purchased 22,388,212 shares of our common stock in the open market for an aggregate cost of \$776.7 million. Treasury shares purchased prior to August 28, 2008 were not subject to the stock split on that date. During the six months ended December 31, 2015, we repurchased 1,668,713 shares of our common stock for a total cost of \$125.0 million. As of December 31, 2015, the remaining available authorization under our common stock repurchase program is \$273.3 million.

**Bank Credit Facility.** On September 30, 2014, we entered into the Credit Agreement, with the Lenders, and Wells Fargo, as Administrative Agent for the Lenders. On October 20, 2015, we entered into a Commitment Increase Agreement and First Amendment to Credit Agreement, or the First Amendment, with the Administrative Agent and each of the lenders party thereto, which amends the Credit Agreement dated September 30, 2014, among us, the Lenders and the Administrative Agent.

Pursuant to the First Amendment, we exercised our right under the Credit Agreement to request a \$100 million increase to the aggregate revolving credit commitment thereunder, for total aggregate revolving credit commitments of \$250 million, and the Lenders under the Credit Agreement agreed to provide such increased revolving credit commitments pursuant to the terms of the First Amendment.

The Credit Agreement provides for, among other things, (i) a revolving credit facility of up to \$150 million, subsequently amended and increased in October 2015 to \$250 million, which includes a \$20 million sublimit for letters of credit and a \$20 million sublimit for swingline loans, and (ii) a term loan facility in an amount of \$150 million. Under the terms of the Credit Agreement, we may, subject to the satisfaction of certain conditions, request increases in the revolving credit facility commitments and additional term loan commitments in an aggregate principal amount of up to \$100 million to the extent existing or new lenders agree to provide such increased or additional commitments, as applicable. We borrowed \$150 million under the term loan facility and \$100 million under the revolving credit facility to finance a portion of the RSP Acquisition purchase price. As of December 31, 2015, the outstanding balance of the debt was \$242.5 million.

Our obligations under the Credit Agreement are guaranteed by the material domestic subsidiaries of our company, subject to certain exceptions (such material subsidiaries, together with our company, collectively, the Credit Parties). The obligations of the Credit Parties under the Credit Agreement and the other loan documents delivered in connection therewith are secured by a first priority security interest in substantially all of the existing and future personal property of the Credit Parties, including, without limitation, 65% of the voting capital stock of certain of the Credit Parties' direct foreign subsidiaries, subject to certain exceptions.

Under our Credit Agreement, the revolving credit facility and term loans bear interest at our election of a Base Rate plus an applicable margin or LIBOR plus an applicable margin. Swingline loans bear interest at a Base Rate plus an applicable margin. The Base Rate is the greater of the Prime Rate, the Federal Funds Rate plus 50 basis points, or LIBOR plus 100 basis points. The applicable margin is based on a sliding scale which ranges from zero to 100 basis points for Base Rate loans and 100 basis points to 200 basis points for LIBOR loans.

The term loan facility requires repayment over five years with nineteen quarterly principal payments beginning in the three months ending March 31, 2015. Each of the first four quarterly principal payments is \$1.9 million, each of the following quarterly principal payments is \$3.8 million, with the final principal payment of \$90.0 million due on September 30, 2019. The revolving credit facility requires payment in full at the end of five years on September 30, 2019. Interest on the term loan facility and revolving credit facility is payable quarterly.

Under the Credit Agreement, there are various restrictive covenants, including three financial covenants which limit the consolidated total leverage ratio, or leverage ratio, the consolidated interest coverage ratio, or interest coverage ratio, and places a restriction on the amount of capital expenditures that may be made in any fiscal year. The leverage ratio is the ratio of debt as of the measurement date to earnings before interest, taxes, depreciation and amortization, or EBITDA, for the four consecutive quarters ending with the quarter of measurement. The leverage ratio must not exceed 2.50 to 1.0 during the first two years of the agreement, and 2.0 to 1.0 during the last three years of the agreement. The interest coverage ratio is EBITDA to interest expense for the four consecutive quarters ending with the quarter of measurement. The interest coverage ratio must not be less than 3.50 to 1.0 during the term of the agreement. As of December 31, 2015, we were in compliance with the restrictive covenants.

**\$100 Million Shelf Registration.** We have registered an aggregate of \$100.0 million of common stock and preferred stock for issuance in connection with acquisitions, which shares will generally be freely tradeable after their issuance under Rule 145 of the Securities Act unless held by an affiliate of the acquired company, in which case such shares will be subject to the volume and manner of sale restrictions of Rule 144 of the Securities Act.

**Liquidity and Capital Resources.** We believe our existing cash and cash equivalents, anticipated cash flows from operating activities, and available credit under our revolving credit facility will be sufficient to meet our working capital and other cash

requirements for at least the next 12 months, including our indemnification holdback liability associated with our acquisition of RSP, our contingent consideration obligations associated with the acquisitions of Validity and Pacinian, and our debt service obligations. Our future capital requirements will depend on many factors, including our revenue, the timing and extent of spending to support product development efforts, costs related to protecting our intellectual property, the expansion of sales and marketing activities, timing of introductions of new products and enhancements to existing products, the costs to ensure access to adequate manufacturing, the costs of maintaining sufficient space for our expanding workforce, the continuing market acceptance of our product solutions, our common stock repurchase program, and the amount and timing of our investments in, or acquisitions of, other technologies or companies. Further equity or debt financing may not be available to us on acceptable terms or at all. If sufficient funds are not available or are not available on acceptable terms, our ability to take advantage of business opportunities or to respond to competitive pressures could be limited or severely constrained.

Our non-current other assets consist of ARS investments, which have failed to settle in auctions. These investments are not liquid, and in the event we need to access these funds, we will not be able to do so without a loss of principal, unless redeemed by the issuers or a future auction on these investments is successful.

Based on our ability to access our cash and cash equivalents, our expected operating cash flows, and our other sources of cash, we do not anticipate that the lack of liquidity on these investments will affect our ability to operate our business as usual. Further, while we do not anticipate the need to remit undistributed earnings of our foreign subsidiaries to meet our working capital and other cash requirements, if we did remit such earnings we would be required to accrue and pay U.S. taxes to repatriate these funds, which would adversely impact our financial position and results of operations.

#### Contractual Obligations and Commercial Commitments

Our material contractual obligations and commercial commitments as of December 31, 2015 were as follows (in millions):

|  | Remaining      |                  |                  |                  |                  |               | Total          |
|--|----------------|------------------|------------------|------------------|------------------|---------------|----------------|
|  | in Fiscal      |                  |                  |                  |                  |               |                |
|  | Year 2016      | Fiscal Year 2017 | Fiscal Year 2018 | Fiscal Year 2019 | Fiscal Year 2020 | Thereafter    |                |
| Long-term debt (1)                             | \$ 9.9         | \$20.7           | \$22.1           | \$23.5           | \$192.5          | \$ -          | \$268.7        |
| Leases   | 4.8            | 6.6              | 3.0              | 1.1              | 0.5              | 0.6           | 16.6           |
| Purchase obligations and other commitments (2) | 16.6           | -                | -                | -                | -                | -             | 16.6           |
| Other long-term obligations (3)                | 68.4           | -                | -                | 24.5             | -                | -             | 92.9           |
| <b>Total</b>                                   | <b>\$ 99.7</b> | <b>\$27.3</b>    | <b>\$25.1</b>    | <b>\$49.1</b>    | <b>\$193.0</b>   | <b>\$ 0.6</b> | <b>\$394.8</b> |

(1) Represents both principal and interest payable through the maturity date of the underlying contractual obligation.

(2) Purchase obligations and other commitments include payments due for inventory purchase obligations with contract manufacturers.

(3) Represents a hold back liability under the definitive agreements for the RSP Acquisition and payments due for contingent consideration.

In fiscal 2015 we completed the acquisition of RSP. The purchase price at the closing date of the acquisition was paid entirely in cash, with ¥7.25 billion held back to address any post-closing adjustments or claims, or indemnification

holdback. We anticipate settlement of the indemnification holdback to occur in the fourth quarter of fiscal 2016. The indemnification hold back liability is \$59.9 million as of December 31, 2015.

In connection with the acquisition of Validity in November 2013, we entered into a contingent consideration arrangement. As of December 31, 2015, we may be required to make additional cash payments of up to \$100.6 million as consideration to the former Validity stockholders and option holders based on unit sales of products utilizing Validity technology through March 2016. We estimated the fair value of the contingent consideration liability as of December 31, 2015 to be \$33.0 million.

In connection with the acquisition of Pacinian in June 2012, we entered into a contingent consideration arrangement and subsequently paid \$5.0 million of additional consideration to the former Pacinian stockholders upon customer acceptance of a ThinTouch product. As of December 31, 2015, we may be required to make additional cash payments of up to \$10.0 million as consideration to the former Pacinian stockholders based on unit sales of products utilizing ThinTouch technology through June 2016. We estimated the fair value of the contingent consideration liability as of December 31, 2015 to be zero.

The amounts in the table above exclude unrecognized tax benefits of \$13.9 million. As of December 31, 2015, we were unable to make a reasonably reliable estimate of when cash settlement with a taxing authority may occur in connection with our gross unrecognized tax benefit.

#### Recently Issued Accounting Pronouncements Not Yet Effective

In January 2016, the FASB issued an accounting standards update, or ASU, on Recognition and Measurement of Financial Assets and Financial Liabilities, which provides guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. This ASU will be effective for us beginning in our first quarter of fiscal 2019. We are evaluating the effects of the adoption of this ASU on our financial statements.

In November 2015, the FASB issued an ASU on Balance Sheet Classification of Deferred Taxes, which eliminates the current requirement to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, entities will be required to classify all deferred tax assets and liabilities as noncurrent. This ASU will be effective for us beginning in our first quarter of fiscal 2018 and early adoption is permitted. We are evaluating the timing of our adoption of this ASU as well as the effects of the adoption of this ASU on our financial statements.

In May 2014, the FASB issued an ASU on Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue which it expects to be entitled to for the transfer of promised goods or services to customers. The new standard will replace most existing revenue recognition guidance in U.S. GAAP when the new standard becomes effective. The new standard is effective for us in our fiscal year 2019. We are evaluating the effect the new standard will have on our consolidated financial statements and related disclosures. The new standard permits the use of either the retrospective or cumulative effect transition method. We have not yet selected a transition method or determined the effect of the standard on our ongoing financial reporting.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As of December 31, 2015, our market risk related to interest rates on our cash and cash equivalents and ARS investments, variable interest rate risk, and foreign currency exchange risks has not changed materially from the risks disclosed in Item 7A of our Annual Report on Form 10-K for the fiscal year ended June 27, 2015.

### ITEM 4. CONTROLS AND PROCEDURES

#### Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, are recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and to reasonably ensure that such information is accumulated and communicated to our management, including the Chief Executive Officer, or CEO, and the Chief Financial Officer, or CFO, as appropriate, to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our management, including our CEO and CFO, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Report. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Report.

#### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the six months ended December 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



PART II—OTHER INFORMATION

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

Our Board of Directors has cumulatively authorized \$1.05 billion for our common stock repurchase program, which expires October 2017. There were no repurchases under our common stock repurchase program during the three-month period ended December 31, 2015.

ITEM 6. EXHIBITS

- 10.1.1 Commitment Increase Agreement and First Amendment to Credit Agreement
- 31.1 Certification of Chief Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1\* Section 1350 Certification of Chief Executive Officer
- 32.2\* Section 1350 Certification of Chief Financial Officer
- 101.INS XBRL Instance Document
- 101.SCH XBRL Taxonomy Extension Schema Document
- 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
- 101.DEF XBRL Taxonomy Extension Definition Linkbase Document
- 101.LAB XBRL Taxonomy Extension Label Linkbase Document
- 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

\*This information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SYNAPTICS INCORPORATED

Date: February 3, 2016    By:    /s/ Richard A. Bergman  
Name: Richard A. Bergman  
Title: President and Chief Executive Officer

Date: February 3, 2016    By:    /s/ Wajid Ali  
Name: Wajid Ali  
Title: Senior Vice President and Chief Financial Officer



INDEX TO EXHIBITS

| Exhibit<br>Number | Exhibit   |
|-------------------|---|
| 10.1.1            | Commitment Increase Agreement and First Amendment to Credit Agreement |
| 31.1              | Certification of Chief Executive Officer                              |
| 31.2              | Certification of Chief Financial Officer                              |
| 32.1*             | Section 1350 Certification of Chief Executive Officer                 |
| 32.2*             | Section 1350 Certification of Chief Financial Officer                 |
| 101.INS           | XBRL Instance Document  |
| 101.SCH           | XBRL Taxonomy Extension Schema Document                               |
| 101.CAL           | XBRL Taxonomy Extension Calculation Linkbase Document                 |
| 101.DEF           | XBRL Taxonomy Extension Definition Linkbase Document                  |
| 101.LAB           | XBRL Taxonomy Extension Label Linkbase Document                       |
| 101.PRE           | XBRL Taxonomy Extension Presentation Linkbase Document                |

\*This information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934